My guess - biggest off label after child Gvhd approval will probably be adult gvhd since diseases are similar, and MSB has good results for both.
I say this as I guess off label use will occur in the same hospitals the doctors and staff are trained, which are specialist cancer hospitals and so have more gvhd than say crohns or ards patients.
I can't imagine hospitals that have no sales team present , requesting training and large scale use for essentialy only off label.
2024 Here we go again., page-375
-
- There are more pages in this discussion • 569 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
0.030(3.06%) |
Mkt cap ! $1.153B | |||
| Open | High | Low | Value | Volume |
| $1.01 | $1.04 | 99.0¢ | $5.111M | 5.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 211966 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 136540 | 9 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |